🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationCompounded sema potency testing — HPLC method validation details

Compounded sema potency testing — HPLC method validation details

HPLC_Greg Tue, Jun 2, 2026 at 12:18 AM 24 replies 814 viewsPage 1 of 5
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Jun 2, 2026 at 12:18 AM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

What I am trying to establish is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. Not looking for reassurance. Looking for the part I have got wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
12 7SallyK_inj, CryptoCarl, MariaRD and 9 others
Reply Quote Save Share Report
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Jun 2, 2026 at 12:28 AM#2
HPLC_Greg said:
They are two different exemptions from the same federal requirements and they buy different things.

HPLC_Greg has the substance of this right. The condition it depends on is worth stating. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Last edited: Jun 2, 2026 at 6:28 AM
11 6JessicaM_2024, TomFromTexas, mike.trainer_LA and 8 others
Reply Quote Save Share Report
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Jun 2, 2026 at 12:38 AM#3
HPLC_Greg said:
They are two different exemptions from the same federal requirements and they buy different things.

This is where I part company with the consensus forming above. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

10 5sarah_TO, wendy_avl, jason_paloalto and 7 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Jun 2, 2026 at 12:48 AM#4

This one has a reasonably settled answer, so here it is. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

9 4hans_munich, jason_sac26, chris_chi24 and 6 others
Reply Quote Save Share Report
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Jun 2, 2026 at 1:43 AM#5
Dr.KarenChen said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Agreed, and mass spec answers a question purity does not: identity. High purity tells you one thing dominates the chromatogram, not that it is the molecule you ordered. A mass within about a dalton of expected is the identity check.

8 3PeptideChemSF, A1cHero_PHX, Dr.RenalNash and 5 others
Reply Quote Save Share Report
1235

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register